Hansoh Pharmaceutical Group Company LimitedHKEX: 3692

Voluntary announcement - collaboration development agreement with ailsynbio

· Issued by Hansoh Pharmaceutical Group Company Limited via HKEXnews

Filed with HKEX · Stock code 3692 · · 2 pages · English

Summary by 6ix AI

Hansoh Pharmaceutical Group Company Limited has announced a collaboration development agreement with AilsynBio Limited, focusing on the discovery of novel oral cyclic peptide drug candidates using AilsynBio's AI platform. Under the agreement, Hansoh will have the rights to select targets and acquire intellectual property rights for the corresponding programs, while AilsynBio will receive payments and royalties based on future sales. The company states that the payments related to this agreement will be recognized as research and development expenditure and do not constitute notifiable transactions under the Listing Rules.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Hansoh Pharmaceutical Group Company Limited on 6ix

Earlier from Hansoh Pharmaceutical

Later from Hansoh Pharmaceutical

All Hansoh Pharmaceutical news releases